These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 8970682)
1. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group. Hermans P; Rozenbaum W; Jou A; Castelli F; Borleffs J; Gray S; Ward N; Gori A; De Bona A; Ferré C; Loncà M; Lang JM; Ammassari A; Clumeck N AIDS; 1996 Dec; 10(14):1627-33. PubMed ID: 8970682 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats. Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530 [TBL] [Abstract][Full Text] [Related]
3. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Miles SA; Mitsuyasu RT; Moreno J; Baldwin G; Alton NK; Souza L; Glaspy JA Blood; 1991 May; 77(10):2109-17. PubMed ID: 1709368 [TBL] [Abstract][Full Text] [Related]
4. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. Kuritzkes DR; Parenti D; Ward DJ; Rachlis A; Wong RJ; Mallon KP; Rich WJ; Jacobson MA AIDS; 1998 Jan; 12(1):65-74. PubMed ID: 9456256 [TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861 [TBL] [Abstract][Full Text] [Related]
6. Haematopoietic growth factors as supportive therapy in HIV-infected patients. Hermans P AIDS; 1995 Dec; 9 Suppl 2():S9-S14. PubMed ID: 8775801 [TBL] [Abstract][Full Text] [Related]
7. Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. Stahel RA; Jost LM; Honegger H; Betts E; Goebel ME; Nagler A J Clin Oncol; 1997 May; 15(5):1730-5. PubMed ID: 9164179 [TBL] [Abstract][Full Text] [Related]
8. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443 [TBL] [Abstract][Full Text] [Related]
9. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study. Shi YK; Chen Q; Zhu YZ; He XH; Wang HQ; Jiang ZF; Chang JH; Liu YP; Wang AL; Luo DY; Zhang Y; Ke XY; Li WL; Zhang WJ; Wang XW; Zhang YP; Wang JM; Liu XQ Anticancer Drugs; 2013 Jul; 24(6):641-7. PubMed ID: 23571496 [TBL] [Abstract][Full Text] [Related]
10. The use of Filgrastim in AIDS-related neutropenia. Welch W; Foote M J Hematother Stem Cell Res; 1999; 8 Suppl 1():S9-16. PubMed ID: 10596030 [TBL] [Abstract][Full Text] [Related]
11. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. Younossi ZM; Nader FH; Bai C; Sjogren R; Ong JP; Collantes R; Sjogren M; Farmer D; Ramsey L; Terra K; Gujral H; Gurung C; Srishord M; Fang Y J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172 [TBL] [Abstract][Full Text] [Related]
12. Biopharmaceutical drug development: Filgrastim (r-metHuG-CSF) use in patients with HIV infection. Foote M; Welch W J Hematother Stem Cell Res; 1999; 8 Suppl 1():S3-8. PubMed ID: 10596029 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study]. Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855 [TBL] [Abstract][Full Text] [Related]
14. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454 [TBL] [Abstract][Full Text] [Related]
15. Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study. Rackoff WR; Orazi A; Robinson CA; Cooper RJ; Alter BP; Freedman MH; Harris RE; Williams DA Blood; 1996 Sep; 88(5):1588-93. PubMed ID: 8781414 [TBL] [Abstract][Full Text] [Related]
16. Low-dose recombinant human granulocyte colony-stimulating factor therapy in children with symptomatic chronic idiopathic neutropenia. Bernini JC; Wooley R; Buchanan GR J Pediatr; 1996 Oct; 129(4):551-8. PubMed ID: 8859262 [TBL] [Abstract][Full Text] [Related]
17. Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer. Rahiala J; Perkkiö M; Riikonen P Med Pediatr Oncol; 1999 May; 32(5):326-30. PubMed ID: 10219332 [TBL] [Abstract][Full Text] [Related]
18. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Maher DW; Lieschke GJ; Green M; Bishop J; Stuart-Harris R; Wolf M; Sheridan WP; Kefford RF; Cebon J; Olver I; McKendrick J; Toner G; Bradstock K; Lieschke M; Cruickshank S; Tomita DK; Hoffman EW; Fox RM; Morstyn G Ann Intern Med; 1994 Oct; 121(7):492-501. PubMed ID: 7520676 [TBL] [Abstract][Full Text] [Related]
19. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Saven A; Burian C; Adusumalli J; Koziol JA Blood; 1999 Apr; 93(8):2471-7. PubMed ID: 10194424 [TBL] [Abstract][Full Text] [Related]
20. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. McQuaker IG; Hunter AE; Pacey S; Haynes AP; Iqbal A; Russell NH J Clin Oncol; 1997 Feb; 15(2):451-7. PubMed ID: 9053465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]